Intervention
SGLT2i
ClinicalTrials.gov intervention label
Clinical trials
7 shownSGLT2i Effect on PTDM Development and Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients: A Randomized, Doubleblind, Placebo Controlled, National Multicenter TrialNCT07682350 · 2026-09-01
NOT_YET_RECRUITINGEfficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney DiseaseNCT07537088 · 2026-05-01
NOT_YET_RECRUITINGImpact of SGLT2 Inhibitors in Heart Transplant RecipientsNCT06147271 · 2023-11-20
UNKNOWNThe Hemodynamic Effects of SGLT2i in Acute Decompensated Heart FailureNCT05346653 · 2023-05-22
TERMINATEDHF Patients With LVADs Being Treated With SGLT2iNCT05278962 · 2022-09-08
COMPLETEDComparison of Type 2 Diabetes Pharmacotherapy RegimensNCT05073692 · 2021-07-01
COMPLETEDReal-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With ObesityNCT05535322 · 2014-01-01
COMPLETEDCommon conditions
Acute Decompensated Heart Failure1Cardiac Allograft Vasculopathy1Cardiovascular Diseases1CKD - Chronic Kidney Disease1Heart Failure With Reduced Ejection Fraction1Kidney Transplant Recipient1Non-Diabetic Patients1Obesity1Placebo Control Design1Post Transplant Diabetes Mellitus1Randomized Controlled Trial (RCT)1Rejection Heart Transplant1Sodium Glucose Co-Transporter 2 Inhibitors1T2DM (Type 2 Diabetes Mellitus)1Transplant; Failure, Heart1Type 2 Diabetes1Type 2 Diabetes Mellitus1
Leading sponsors
Trial status mix
COMPLETED3
NOT_YET_RECRUITING2
TERMINATED1
UNKNOWN1
Phase mix
PHASE43
PHASE22
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.